Baxter Healthcare partly prevails in US norepinephrine patent row with Nevakar
Construction in 2023 of “chelating agent” in a patent covering a formulation of norepinephrine proved fatal Friday to literal direct infringement allegations leveled by Nevakar Injectables against Baxter Healthcare, but a...To view the full article, register now.
Already a subscriber? Click here to view full article